Stocktoria

Alto Neuroscience, Inc. ANRO

NYSE · stock · Pharmaceutical Preparations · website · IPO 2024-02-02

Alto Neuroscience, Inc. statistics & valuation

Market cap$948.9M
P / B6.3×
Return on equity-41.8%
Net cash$160.3M
Enterprise value USD$788.6M
Earnings yield EBIT/EV-8.4%
Return on capital-38.3%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202320242025
Operating margin (%)
202320242025
Return on equity (%)
-40.60% -41.80% 202320242025
Shares outstanding
3.8M 27.0M 31.9M 202320242025
Net debt ($)
-$72.7M -$158.0M -$160.3M 202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-41.90% -34.60% -34.20% 202320242025
Free cash flow margin (%)
202320242025
Debt / equity (×)
0.07× 0.11× 202320242025
EPS ($)
-$9.73 -$2.50 -$2.19 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Return on assets-34.2%-34.6%-41.9%
Return on equity-41.8%-40.6%50.7%
Debt / equity0.11×0.07×-0.14×
Current ratio15.6916.9215.22

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.